stars 1 stars 2 stars 3

Beta-O2 is developing the ßAir Bio-artificial Pancreas, intended to cure Type 1 diabetes (TID). Patients with TID are unable to produce insulin, a hormone needed to transport sugar into cells, providing the energy needed for daily life. ßAir provides a viable and safe environment for islets of Langerhans (insulin producing beta cells), to thrive and provide the body with insulin on demand. It is able to do so, as Beta-O2 has solved the major challenges of islet transplantation – creating a protective environment where the cells can thrive but where the patient doesn’t need to take life-long immunosuppression drugs with unpleasant side effects, and of crucial importance, keeping the cells alive and functioning inside the recipient’s body.

Beta-o2 Technologies Ltd. Questions

The Beta-o2 Technologies Ltd. annual revenue was $6.2 million in 2026.

Konstantin Bloch is the Scientific co-founder of Beta-o2 Technologies Ltd..

5 people are employed at Beta-o2 Technologies Ltd..

The NAICS codes for Beta-o2 Technologies Ltd. are [325, 32, 3254, 32541].

The SIC codes for Beta-o2 Technologies Ltd. are [283, 28].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users